pneumocystis carinii

(redirected from pneumocystis pneumonia)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to pneumocystis pneumonia: cytomegalovirus, tuberculosis, toxoplasmosis, Pneumocystis jiroveci, Kaposi Sarcoma

pneumocystis carinii:

see pneumoniapneumonia
, acute infection of one or both lungs that can be caused by a bacterium, usually Streptococcus pneumoniae (also called pneumococcus; see streptococcus), or by a virus, fungus, or other organism.
..... Click the link for more information.
References in periodicals archive ?
Use of nasopharyngeal aspirate for diagnosis of Pneumocystis pneumonia.
Serum indicators for the diagnosis of pneumocystis pneumonia.
In the blinded study, investigators compared quantitative touch-down polymerase chain reaction (QTD PCR) results with bronchoscopy with bronchoalveolar lavage (BAL), which is widely considered to be the standard for the diagnosis of Pneumocystis pneumonia (PCP).
Friedman-Kien, A and others, "Kaposi's sarcoma and pneumocystis pneumonia among homosexual Men-New York City and California," Morbidity and Mortality Weekly Report, 1981: 30: 305-08.
These data support further development of MiniVax's technology as a vaccine for Pneumocystis pneumonia (PCP).
Patients with pneumocystis pneumonia who require mechanical ventilation have a high risk of mortality.
After receiving recommendations from the Data Safety Monitoring Board, the Steering Committee for the pneumocystis pneumonia (PCP) study and others, and in consultation with the US Food and Drug Administration (FDA) and Immtech's licensing partners, including Strativa, Immtech has chosen to discontinue the development program for pafuramidine.
But in 1993 I developed the first of many opportunistic infections, Pneumocystis pneumonia, and began the first of many hospital stays.
Brown has over 15 years of experience in fungal infection and immunology research and will help further develop MiniVax's novel vaccine for preventing Pneumocystis pneumonia (PCP), a deadly fungal infection of the lungs that predominantly affects immunocompromised patients such as HIV/AIDS patients.
Pneumocystis pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.
Additionally, the potential benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this target market.